Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Total debt
Vertex Pharmaceuticals Incorporated's total debt at the end of fiscal 2024 was $112.8M, down 70.0% from $376.1M in fiscal 2023. At the end of the quarter to 31 March 2025 it was $111.4M. Over the past ten years it has ranged from $112.8M (fiscal 2024) to $821.3M (fiscal 2016) — the current reading is the lowest in ten years. Vertex Pharmaceuticals Incorporated ranks 77th of 590 Biotechnology companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2024 | $112.8M | (70.01%) |
| FY2023 | $376.1M | (27.65%) |
| FY2022 | $519.8M | (11.87%) |
| FY2021 | $589.8M | (0.37%) |
| FY2020 | $592.0M | 0.58% |
| FY2019 | $588.6M | (0.50%) |
| FY2018 | $591.6M | (2.53%) |
| FY2017 | $606.9M | (26.11%) |
| FY2016 | $821.3M | 1.31% |
| FY2015 | $810.7M | — |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Mar 2025 | $111.4M | (1.24%) |
| Dec 2024 | $112.8M | (1.05%) |
| Sep 2024 | $114.0M | (67.11%) |
| Jun 2024 | $346.6M | (4.12%) |
| 37 more quarters | Free account |
Against its own ten years
Low $112.8M
High $821.3M
Ten-year median
$590.7M
Current reading's percentile
10
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $9.0B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $2.0B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $882.2M |
| MRNA Moderna, Inc. compare | $597.0M |
| INSM Insmed, Inc. compare | $562.4M |
| VRTX Vertex Pharmaceuticals Incorporated | $111.4M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement